ArticleClinical rheumatology2026
A bibliometric analysis on immunotherapy treatments for systemic lupus erythematosus: analysis of published evidence from 2014 to 2024.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundImmunotherapy has been widely used in systemic lupus erythematosus (SLE) research. We analyzed the published articles on SLE immunotherapy to understand the research trends and hot topics in this field.
methodsEnglish-language literature on SLE immunotherapy was searched from Web of Science Core Collection database for the period 2014-2024 incorporating both review articles and articles. Temporal publication patterns, inter-institutional cooperative networks, and emerging thematic priorities within this investigative sphere were rigorously analyzed through computational scientometric examination using CiteSpace analytical software.
resultsFrom an initial dataset of 402 articles, 374 records satisfied inclusion parameters for comprehensive evaluation. The USA (141 articles) emerged as the predominant contributor, with Harvard University (31 articles) representing the most productive institutional entity. At the individual investigator level, Abdel-Wahab, Noharas (4 articles) identified as the most prolific contributor. The highest-cited reference was Mackensen A (2022) with 20 citations. Co-citation network clustering revealed ten principal research domains: forkhead box P3, ICIs, SLE, multiple sclerosis, expression, systemic autoimmunity, term follow-up, n6-methyladenosine, T cells, and antiphospholipid syndrome. Temporal keyword analysis detected emerging investigative priorities including risk (strength 3.46), double blind (strength 3.2), primary Sjogrens syndrome (strength 3.13), low-dose interleukin 2 (strength 3.05), and cutting edge (strength 3.02).
conclusionsThis scientometric evaluation of 374 scholarly works emphasizes the critical importance of transnational collaborations among premier research institutions and developed nations in propelling SLE immunotherapy innovation. This bibliometric analysis reveals research trends and unmet needs in SLE immune therapies, guiding biologics development and precision medicine through core pathway identification and optimized trial designs. Key Points • Global research mapping: Identification of the USA (141 articles) and Harvard University (31 articles) as the predominant national and institutional contributors, respectively. • Intellectual structure analysis: Co-citation network clustering revealed ten principal research domains, including forkhead box P3, ICIs, n6-methyladenosine, and antiphospholipid syndrome, delineating the foundational knowledge structure. • Emerging frontiers detection: Temporal keyword analysis pinpointed evolving research priorities such as low-dose interleukin 2 (burst strength: 3.05), double-blind trials (strength: 3.2), and primary Sjögren's syndrome (strength: 3.13). • Strategic implications: The study underscores the critical role of transnational collaborations in advancing SLE immunotherapy innovation and highlights unmet needs guiding future biologics development and precision medicine approaches through core pathway identification and optimized trial designs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.